Stocksigma LogoStocksigma Logo

Tavexia Lifecare Acquires 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore

On 12th Oct'26, Tavexia Lifecare approved acquiring a 60% controlling stake in Meyonex Pharmaceuticals for ₹67.19 Crore via cash subscription of

Tavexia Lifecare Acquires 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore

Sattva Sukun Lifecare Ltd · Others (Uncategorized) · 13 Oct 2026, 12:14 am

Tavexia Lifecare Acquires 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore On 12th Oct'26, Tavexia Lifecare approved acquiring a 60% controlling stake in Meyonex Pharmaceuticals for ₹67.19 Crore via cash subscription of 2,09,97,180 fresh equity shares at ₹32 per share. The acquisition provides immediate manufacturing capacity at MIDC Tarapur, Maharashtra. Alongside altering its Memorandum of Association, Tavexia is expanding into APIs, finished dosage formulations, CDMO/CRAMS, and nutraceuticals to capitalize on "China+1" tailwinds. The company plans to fund this roadmap through equity or convertible instruments.

Original exchange filing (PDF)

More announcements from Sattva Sukun Lifecare Ltd

All Sattva Sukun Lifecare Ltd announcements